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Summary
Sir2 NAD-dependent deacetylases connect transcription, metabolism, and aging. Increasing the dosage or activity of Sir2
extends life span in yeast, worms, and flies and promotes fat mobilization and glucose production in mammalian cells.
Here we show that increased dosage of Sirt1, the mammalian Sir2 ortholog, in pancreatic β cells improves glucose toler-
ance and enhances insulin secretion in response to glucose in beta cell-specific Sirt1-overexpressing (BESTO) transgenic
mice. This phenotype is maintained as BESTO mice age. Pancreatic perfusion experiments further demonstrate that Sirt1
enhances insulin secretion in response to glucose and KCl. Microarray analyses of β cell lines reveal that Sirt1 regulates
genes involved in insulin secretion, including uncoupling protein 2 (Ucp2). Isolated BESTO islets also have reduced Ucp2,
increased ATP production, and enhanced insulin secretion during glucose and KCl stimulation. These findings establish
the importance of Sirt1 in β cell function in vivo and suggest therapeutic interventions for type 2 diabetes.Introduction
Silent information regulator 2 (Sir2) proteins are an evolution-
arily conserved family of NAD-dependent protein deacetylases
(Imai et al., 2000; Landry et al., 2000; Smith et al., 2000). In a
wide variety of experimental organisms, Sir2 proteins regulate
aging and longevity (Bordone and Guarente, 2005). Genetic
and chemical manipulations that increase the dosage or activ-
ity of Sir2 proteins dramatically extend the life spans of yeast,
worms, and flies, while deletions or mutations of the Sir2 genes
shorten their life spans (Astrom et al., 2003; Howitz et al., 2003;
Kaeberlein et al., 1999; Rogina and Helfand, 2004; Tissenbaum
and Guarente, 2001; Wood et al., 2004). Sir2 proteins also con-
nect nutritional and hormonal cues to the regulation of life
span. Caloric restriction, the most consistent regimen to retard
aging and extend longevity in many different species, requires
the Sir2 genes for life span extension in Saccharomyces cere-
visiae and Drosophila melanogaster (Anderson et al., 2003; Lin
et al., 2000; Lin et al., 2004; Lin et al., 2002; Rogina and Hel-
fand, 2004). Additionally, the Sir2 ortholog SIR-2.1 in Caeno-
rhabditis elegans promotes longevity via the forkhead tran-
scription factor DAF-16 in the highly conserved insulin-like
signaling pathway (Tissenbaum and Guarente, 2001). This
pathway has been demonstrated to play a critical role in regu-
lating aging in worms, flies, and mice (Guarente and Kenyon,
2000; Tatar et al., 2003).
While it is not yet clear whether Sir2 similarly regulates aging
and longevity in mammals, the Sir2 ortholog, Sirt1/Sir2α, has
been shown to regulate metabolism in response to nutrient
availability (Bordone and Guarente, 2005). Nutrient deprivation
in mammalian cells results in an increase in Sirt1 expression
dependent upon the forkhead transcription factor Foxo3 and
the tumor suppressor p53 (Nemoto et al., 2004). Likewise, dur-CELL METABOLISM : AUGUST 2005 · VOL. 2 · COPYRIGHT © 2005 ELSing fasting and caloric restriction in rodents, Sirt1 mRNA and
protein levels are upregulated in tissues such as muscle, brain,
liver, and fat (Al-Regaiey et al., 2004; Cohen et al., 2004; Ne-
moto et al., 2004; Rodgers et al., 2005). Increased dosage or
activity of Sirt1 in adipocytes triggers lipolysis and promotes
free fatty acid mobilization by repressing PPAR-γ, a nuclear re-
ceptor that promotes adipogenesis (Picard et al., 2004). Sirt1
also regulates the gluconeogenic and glycolytic pathways in
liver in response to fasting by interacting with and deacetylat-
ing PGC-1α, a key transcriptional regulator of glucose produc-
tion in the liver (Rodgers et al., 2005). These results indicate
that Sirt1 regulates metabolic responses to changes in nutrient
availability in a wide variety of tissues.
Pancreatic β cells play a central role in maintaining glucose
homeostasis in mammals by secreting insulin in response to
elevated blood glucose levels. β cells have a highly coordi-
nated mechanism that senses glucose and transduces its sig-
nal to insulin secretion. Glucose, which enters the β cells via
GLUT2 glucose transporters, is metabolized during glycolysis,
resulting in an increase in the ATP/ADP ratio. Subsequent clo-
sure of ATP-dependent K+ (KATP) channels causes membrane
depolarization, thereby opening voltage-gated Ca2+ channels.
The inward Ca2+ flux ultimately triggers exocytosis of insulin-
containing granules. Based on the fact that Sir2 proteins con-
nect nutrient availability to longevity and our finding that β cells
express Sirt1 in pancreatic islets, we hypothesized that Sirt1
plays an important role in the regulation of insulin secretion and
that increasing the dosage of Sirt1 in β cells conveys beneficial
effects on glucose homeostasis. Here we show that pancreatic
beta cell-specific Sirt1-overexpressing (BESTO) transgenic
mice exhibit improved glucose tolerance and enhanced insulin
secretion when challenged with high glucose. This phenotype
is maintained as BESTO mice age. In situ pancreatic perfusionEVIER INC. DOI 10.1016/j.cmet.2005.07.001 105
A R T I C L Eexperiments further demonstrate enhanced insulin secretion in
BESTO pancreata during glucose and potassium chloride (KCl)
stimulation. Gene expression analyses on Sirt1-overexpressing
and Sirt1-knockdown pancreatic β cell lines show that Sirt1
regulates a variety of genes involved in β cell function, includ-
ing Ucp2, an uncoupling protein that negatively regulates insu-
lin secretion in β cells. Consistent with these results, isolated
BESTO islets have reduced Ucp2 and increased ATP levels and
exhibit enhanced insulin secretion in response to both glucose
and KCl. Together, these results establish that an increased
dosage of Sirt1 has beneficial effects on mammalian physiol-
ogy in vivo. Our findings also provide new insight into the phys-
iological and molecular functions of Sirt1 in glucose metabo-
lism and suggest therapeutic interventions for the prevention
and treatment of age-associated metabolic disorders, such as
type 2 diabetes mellitus.
Results
Sirt1 is expressed in pancreatic β cell lines
and mouse islets
To examine the connection between Sirt1 and β cell function,
we first assessed the expression levels of the Sirt1 protein in
two pancreatic β cell lines, MIN6 (mouse) and INS1 (rat), and
in primary islets isolated from C57BL/6 mice (Figure 1A). Mod-
erate levels of Sirt1 were detected in MIN6 and INS1 cell lines
compared to a relatively high expression level of Sirt1 in the
mouse NIH3T3 fibroblast cell line. An intermediate level of Sirt1
was also detected in whole pancreatic extracts compared to
low and high levels of Sirt1 in brain and testis extracts, respec-
tively (Figure 1A). Most importantly for our studies, Sirt1 was
expressed in isolated mouse islets (Figure 1A). To examine the
distribution of Sirt1 in the pancreas, we immunostained Sirt1
on mouse pancreatic sections with an antibody against the
N-terminal portion of Sirt1. Strikingly, Sirt1 was expressed spe-
cifically in pancreatic islets and not in pancreatic exocrine tis-
sues (Figure 1B), suggesting a role for Sirt1 in pancreatic en-
docrine function. Within the islets, β cells had a weak, punctate
Sirt1 signal in the nucleus and a diffusely distributed signal in
the cytoplasm, although the signal intensity varied from cell to
cell (Figures 1B, 1C, and 1E). Immunostaining of testis sections
showed that Sirt1 was expressed exclusively in the nuclei of
spermatogenic cells (Figure 1D), a positive control consistent
with previous reports (McBurney et al., 2003). An antibody
against the C-terminal portion of Sirt1 also showed similar
staining patterns in pancreatic islets (data not shown). There-
fore, it is unlikely that the cytoplasmic staining in β cells is sim-
ply due to nonspecific crossreactivity of the antibody. Interest-
ingly, glucagon-positive α cells exhibited strong, exclusive
cytoplasmic staining of Sirt1 (Figures 1E–1G). The biological
role of this cytoplasmic Sirt1 in α cells is currently unknown.
The nuclear and cytoplasmic distribution of Sirt1 in β cells and
the central role of β cells in glucose metabolism prompted us
to investigate whether Sirt1 could play a role in the regulation
of β cell function and glucose homeostasis in mammals.
Production of BESTO transgenic mice
We generated BESTO transgenic mice in order to address the
hypothesis that increased Sirt1 dosage in β cells might convey
beneficial effects on β cell function in mammals. In these mice,
a 1.9 kb fragment of the human insulin promoter, which has106been demonstrated to mediate pancreatic β cell-specific tran-
scription in mice (Hotta et al., 1998; Yamamoto et al., 2003),
drives expression of the mouse Sirt1 cDNA (Figure 2A). Two
independent BESTO transgenic lines, 431-2 and 431-4, were
established on the C57BL/6 inbred background. Sirt1 was
overexpressed 12- and 18-fold in islets isolated from mice from
lines 431-2 and 431-4, respectively, compared to control non-
transgenic siblings (Figure 2B). The β cell-specific overexpres-
sion of Sirt1 was confirmed by immunostaining pancreatic sec-
tions of BESTO mice (Figure 2C). Strong nuclear staining of
Sirt1 was observed in insulin-positive β cells but not in gluca-
gon-positive α cells of the BESTO mice, although the levels of
Sirt1 expression varied from cell to cell and from islet to islet
(Figure 2C). No obvious overexpression of Sirt1 was detected
by Western blotting and immunostaining of other tissues, in-
cluding brain, liver, kidney, adipose tissue, and muscle (data
not shown). BESTO mice from both lines 431-2 and 431-4 did
not show any gross abnormalities and did not differ in body
weight from their nontransgenic siblings up to 18 months of
age (data not shown). We also determined whether the in-
creased dosage of Sirt1 affected islet structure by measuring
the percent islet area and the β cell mass. BESTO mice and
their controls did not differ significantly in either parameter (Fig-
ures 2D and 2E). Additionally, the pancreatic insulin content
did not differ statistically between BESTO and control mice,
although some BESTO mice showed slightly higher values
(data not shown).
BESTO mice exhibit improved glucose tolerance and
enhanced insulin secretion in response to high glucose
To examine the effects of increased Sirt1 dosage on β cell
function in vivo, we first measured blood glucose and plasma
insulin levels in the BESTO mice. At 3 months of age, fed and
fasted glucose levels were similar between transgenic mice
and their nontransgenic siblings in both the 431-2 and 431-4
lines (Figure 3A). Fed and fasted insulin levels also did not differ
between transgenic mice and their controls in both BESTO
lines (Figure 3B and 0 min time points in Figure 3E).
However, when challenged with high glucose in an intraperi-
toneal glucose tolerance test (IPGTT), both male and female
BESTO mice in both lines showed significantly improved glu-
cose tolerance compared to their nontransgenic siblings (Fig-
ures 3C and 3D). We measured insulin levels at 0 and 30 min
time points during the IPGTTs. Consistent with their improved
glucose tolerance, plasma insulin levels 30 min after glucose
injection were significantly higher in male BESTO mice com-
pared to their nontransgenic siblings (Figure 3E, left panel). Fe-
males also showed a similar trend, although the difference was
not statistically significant (Figure 3E, right panel). These find-
ings suggest that an increased dosage of Sirt1 in pancreatic β
cells enhances their ability to secrete insulin and reduce blood
glucose levels in response to high glucose in vivo.
In situ-perfused pancreata of BESTO mice show
enhanced insulin secretion
In order to further confirm that insulin secretion is enhanced in
BESTO pancreata in response to high glucose, we conducted
in situ pancreatic perfusion experiments in BESTO and control
mice. Total insulin release in response to 25 mM glucose was
significantly enhanced in BESTO pancreata compared to con-
trols (Figures 4A and 4B, left panel). This increased insulin re-CELL METABOLISM : AUGUST 2005
Sirt1 regulates pancreatic β cell function in miceFigure 1. Expression of Sirt1 in pancreatic β cell lines and islets
A) Western blot analysis of Sirt1 in extracts prepared from NIH3T3 mouse fibroblasts, MIN6 and INS1 pancreatic β cell lines, pancreas, brain, and testis. Cell and
tissue extracts (30 and 45 g) were blotted in two separate membranes, respectively. For mouse islets, Sirt1 was first immunoprecipitated from 270 g of extract with
the anti-Sirt1 antibody and immunoblotted. Actin was used as a loading control.
B–D) (B) Immunostaining of Sirt1 with an N-terminal Sirt1 antibody (green) on mouse pancreatic sections. No signal was detected with a rabbit IgG control (data not
shown). (C) Higher magnification of one of the islets shown in (B) showed weak, punctate signals (arrows) in the nucleus as well as diffusely distributed signals in the
cytoplasm of β cells. (D) Immunostaining of Sirt1 with the N-terminal antibody in the testis served as a positive control for the nuclear localization of Sirt1.
E–H) Sirt1 ([E], green) and glucagon ([F], red) were coimmunostained on the same mouse pancreatic section, and the merged image (G) is shown with Hoechst dye
staining of the nuclei (blue). Insulin ([H], red) was stained on an adjacent section.lease by BESTO pancreata was mainly due to an increase in
first-phase insulin secretion (Figure 4B, left panel). We also ex-
amined the response of BESTO pancreata to KCl, a potent se-
cretagogue of insulin secretion, in the same perfusion experi-
ments (Figure 4A). In response to KCl, BESTO pancreata
showed an even more pronounced increase in insulin secretion
compared to controls (Figures 4A and 4B, right panel). These
results further support the notion that the insulin-secretion ca-
pability of β cells is enhanced by Sirt1 in BESTO mice.
BESTO mice maintain improved β cell function
as they age
Because Sir2 is considered to be an important link between
metabolism and aging, we next examined whether the same
cohorts of BESTO mice still maintain enhanced β cell functionCELL METABOLISM : AUGUST 2005compared to controls at a later age. As at 3 months, fed and
fasted glucose and insulin levels of BESTO mice were similar
to those of controls at 8 months of age (Figures 5A and 5B,
and 0 min time points in Figure 5E). Furthermore, 8-month-
old BESTO mice still maintained improved glucose tolerance
compared to controls (Figures 5C and 5D). Although male BE-
STO mice in line 431-4 did not show a statistically significant
improvement, we suspect that this was due to the smaller
number of available individuals in this cohort for the 8 month
analysis. Plasma insulin levels were also higher 30 min after
glucose injection in 8-month-old male BESTO mice compared
to controls in both lines (Figure 5E, left panel, and data not
shown). Female BESTO mice at 8 months of age did not show
a statistically significant difference in plasma insulin levels in
both lines, although the trend was similar to the 3 month data107
A R T I C L EFigure 2. Generation of BESTO transgenic mice
A) Schematic representation of the pIns-Sirt1 transgene used to generate the BESTO mice. The transgene contains a 1.9 kb fragment of the human insulin promoter,
rabbit β-globin introns, the 2.2 kb mouse Sirt1 cDNA, and a polyadenylation signal (pA) from the rabbit β-globin gene (Miyazaki et al., 1990).
B) Western blot analysis of Sirt1 expression in transgenic and control islet extracts. Islets were pooled from three mice from lines 431-2 and 431-4. Actin was used as
a loading control for normalization.
C) Immunostaining of Sirt1 (green) in transgenic (upper panel) and control (lower panel) pancreatic sections from line 431-2. Equal exposure times were applied to the
transgenic and control samples. Glucagon (red) was costained with Sirt1, and the merged image is shown with Hoechst dye staining the nuclei (blue). Insulin (red) was
stained on adjacent sections. Similar overexpression was seen in line 431-4.
D and E) (D) Percent islet area and (E) β cell mass in 4-month-old BESTO transgenic male mice from line 431-4 compared to controls (n = 4). All results are expressed
as mean ± SE.(Figure 5E, right panel, and data not shown). Taken together,
these data indicate that increased dosage of Sirt1 in pancreatic
β cells is able to convey beneficial effects on glucose metabo-
lism at both 3 and 8 months of age by improving glucose toler-
ance and enhancing insulin secretion in response to high
glucose.108Sirt1 regulates the expression of genes important
for β cell function
To dissect the molecular mechanisms by which Sirt1 regulates
β cell function, we employed gene expression profiling to iden-
tify genes that are affected by changing the dosage of Sirt1 in
pancreatic β cells. For this purpose, we established two inde-CELL METABOLISM : AUGUST 2005
Sirt1 regulates pancreatic β cell function in miceFigure 3. Blood glucose, plasma insulin, and
IPGTTs in BESTO transgenic mice at 3 months of
age
A) Fed and fasted blood glucose levels in male (M)
and female (F) BESTO transgenic mice (black bars)
compared to controls (white bars) in lines 431-2 and
431-4 (n = 10–22).
B) Fed plasma insulin levels in male (M) and female
(F) BESTO transgenic mice (black bars) compared
to controls (white bars) in lines 431-2 and 431-4 (n =
8–13).
C and D) IPGTTs in male and female BESTO trans-
genic mice (closed circles) compared to controls
(open circles) in lines 431-2 and 431-4. Following a
15 hr fast, 2 g of 50% glucose (w/v) per kg body
weight was injected intraperitoneally, and blood glu-
cose values were assessed at 0, 15, 30, 60, and 120
min post injection. (C) Line 431-2. BESTO males
(n = 14), control males (n = 15), BESTO females (n =
8), control females (n = 9). (D) Line 431-4. BESTO
males (n = 15), control males (n = 10), BESTO fe-
males (n = 11), control females (n = 11).
E) Plasma insulin levels in male (left panel) and fe-
male (right panel) BESTO transgenic mice (black
bars) compared to controls (white bars) in line
431-4 at 0 and 30 min time points in IPGTTs shown
in Figure 3D. BESTO males (n = 13), control males
(n = 8), BESTO females (n = 10), control females (n =
10). ‡, measurements in both transgenic and control
female mice lower than the detectable limit of 0.156
ng/ml were averaged as 0.156 ng/ml.
All results are expressed as mean ± SE. *p % 0.05,
**p % 0.01, ***p % 0.001.pendent MIN6 cell lines overexpressing Sirt1 (MIN6-Sir2OE1
and 2), as well as two control cell lines carrying the neomycin-
resistance gene only (MIN6-NEO1 and -2). MIN6-Sir2OE1 and
-2 showed 7.6- and 8.5-fold higher expression levels of Sirt1
compared to controls (Figure 6A). We also established two in-
dependent MIN6 cell lines that constitutively expressed two
different small interfering RNAs (siRNAs) against the Sirt1 gene.
In these Sirt1-knockdown MIN6 cell lines (MIN6-Sir2KD1 and
-2), Sirt1 expression levels were reduced to 28% and 53%,
respectively, of the control cell line carrying the backbone vec-
tor (MIN6-mU6pro) (Figure 6B). Using these experimental and
control cell lines, microarray experiments were conducted with
dye swaps and strict filtering criteria (Figure 6C, see Supple-CELL METABOLISM : AUGUST 2005mental Experimental Procedures in the Supplemental Data
available with this article online). Forty-one downregulated and
24 upregulated transcripts were identified in Sir2OE cell lines
(see Table S1), while 24 upregulated and 18 downregulated
transcripts were identified in Sir2KD cell lines (see Table S2).
As expected, there was a statistically significant overlap in the
genes that changed in Sir2OE and Sir2KD cell lines as deter-
mined by the hypergeometric distribution (p = 2.65 − 10−12,
data not shown). Microarray results (deposited into the NCBI
GEO database as series GSE2365) were confirmed by measur-
ing transcript levels of several genes whose expression was
changed by Sir2 overexpression, knockdown, or both (Figure
6D). Gene expression changes measured by quantitative real-109
A R T I C L EFigure 4. In situ pancreatic perfusion experiments in BESTO transgenic mice
A) Insulin release from perfused pancreata of male BESTO (n = 5) and control (n =5) mice from line 431-4 in response to 25 mM glucose (black bar) and 25 mM KCl
(gray bar). The two arrows indicate the start of first and second phase insulin secretion, respectively. All results are expressed as mean ± SE.
B) Area under the curve, representing the amount of insulin release, was calculated for each time interval during glucose (left panel) and KCl (right panel) stimulation.
The brackets in the left panel indicate total, first, and second phase insulin secretion during glucose stimulation. The bracket in the right panel indicates total insulin
secretion during KCl stimulation. The Wilcoxon matched pairs test was employed to determine significance: **p % 0.01; ***p % 0.001; NS, not significant.time RT-PCR were statistically significant and highly consistent
with the microarray results (Figure 6D).
The gene expression profiles revealed that Sirt1 regulates
expression of genes involved in β cell physiology and glucose
homeostasis. For example, the uncoupling protein 2 gene
(Ucp2), the prolactin receptor gene (Prlr), and the urocortin 3
gene (Ucn3) were downregulated in Sir2OE cell lines and/or
upregulated in Sir2KD cell lines (Figure 6D). Ucp2 is a member
of the mitochondrial inner membrane proton transporters that
uncouple respiration from ATP synthesis by leaking protons
from the intermembrane space to the matrix side of the inner
membrane (Chan et al., 2004). It has been demonstrated that
Ucp2 negatively regulates glucose-stimulated insulin secretion
and is a key component of β cell glucose sensing (Joseph et
al., 2002; Zhang et al., 2001). Signaling from the prolactin re-
ceptor is also important in regulating islet mass and glucose110sensitivity during pregnancy (Amaral et al., 2004), and prolactin
receptor-deficient islets show defects in insulin production and
glucose-stimulated insulin secretion (Freemark et al., 2002).
Ucn3, a high-affinity ligand for the type 2 corticotropin-releas-
ing factor receptor, is secreted by pancreatic islets and MIN6
cells and stimulates insulin and glucagon secretion in vitro and
in vivo (Li et al., 2003). The large conductance calcium-acti-
vated potassium channel gene (Kcnmb4) and the monocarbox-
ylic acid transporter gene (Mct1) were upregulated in Sir2OE
cell lines but not significantly changed in Sir2KD cell lines (Fig-
ure 6D). The large conductance calcium-activated potassium
channels are speculated to cause the primary repolarizing cur-
rent and serve to terminate glucose-initiated electrical bursting
in β cells (Li et al., 1999). Mct1 transports pyruvate and lactate
through the plasma membrane. It has been reported that in-
creased Mct1 and lactate dehydrogenase activities result inCELL METABOLISM : AUGUST 2005
Sirt1 regulates pancreatic β cell function in miceFigure 5. Blood glucose, plasma insulin, and
IPGTTs in BESTO transgenic mice at 8 months of
age
A) Fed and fasted blood glucose levels in male (M)
and female (F) BESTO transgenic mice (black bars)
compared to controls (white bars) in lines 431-2 and
431-4 (n = 10–22).
B) Fed plasma insulin levels in male (M) and female
(F) BESTO transgenic mice (black bars) compared
to controls (white bars) in lines 431-2 and 431-4 (n =
6–16).
C and D) IPGTTs in male and female BESTO trans-
genic mice (closed circles) compared to controls
(open circles) in lines 431-2 and 431-4. These mice
were the same mice used for the 3 month analyses
shown in Figure 3. (C) Line 431-2. BESTO males
(n = 11), control males (n = 11), BESTO females (n =
7), control females (n = 9). (D) Line 431-4. BESTO
males (n = 7), control males (n = 5), BESTO females
(n =11), control females (n =11).
E) Plasma insulin levels in male (left panel) and fe-
male (right panel) BESTO transgenic mice (black
bars) compared to controls (white bars) in line
431-2 at 0 and 30 min time points in IPGTTs shown
in Figure 5C. BESTO males (n = 16), control males
(n = 18), BESTO females (n = 12), control females
(n = 16).
All results are expressed as mean ± SE. *p % 0.05,
**p % 0.01, ***p % 0.001.pyruvate- and lactate-stimulated insulin secretion in isolated
rat islets (Ishihara et al., 1999).
It is still unclear to what extent each gene expression change
contributes to the Sir2-dependent regulation of β cell function.
Nevertheless, the fact that Sirt1 affects a wide variety of genes
involved in the regulation of insulin secretion is consistent with
our hypothesis that Sirt1 plays an important role in the regula-
tion of β cell function and glucose homeostasis.
Islets from BESTO mice show enhanced insulin secretion
with decreased amounts of Ucp2 and increased
ATP production
Among the genes identified from the microarray analyses, we
examined several gene products by Western blot analysis inCELL METABOLISM : AUGUST 2005islets isolated from BESTO and control mice. Based on the
availability of appropriate antibodies, we chose Ucp2, Glut2,
Kcnmb4, and Mct1 (Figure 7A). Three of the four gene prod-
ucts, Ucp2, Glut2, and Kcnmb4, changed in the same direction
as in the microarray and quantitative real-time RT-PCR. Ucp2
decreased approximately 1.8-fold, Kcnmb4 increased approxi-
mately 1.5-fold, and Glut2 showed a marginal decrease com-
pared to controls (Figure 7B). However, Mct1 decreased
approximately 1.5-fold compared to controls, a change in di-
rection opposite to that seen in the microarray and RT-PCR
results (Figure 7B).
The downregulation of Ucp2 in BESTO islets was particularly
intriguing because the reduction in Ucp2 levels was consistent
with the observed increase in insulin secretion in BESTO mice111
A R T I C L EFigure 6. Gene expression profiling in Sirt1-overex-
pressing and Sirt1-knockdown pancreatic β cell
lines
A) Western blot analysis of Sirt1 in MIN6 cell lines
independently infected with pBabe-Neo (MIN6-
NEO1 and NEO2) or pBabe-Sirt1 (MIN6-Sir2OE1
and Sir2OE2) retrovirus. The asterisk indicates non-
specific crossreacting bands that serve as loading
controls.
B) Western blot analysis of Sirt1 in MIN6 cell lines
independently cotransfected with the mU6pro plas-
mid (MIN6-mU6pro) or one of two different Sirt1-
siRNA expression vectors (MIN6-Sir2KD1 and
Sir2KD2) and a plasmid carrying a neomycin-resis-
tant gene.
C) Scheme of microarray experiments. Four micro-
array hybridizations with dye swaps were con-
ducted for each pairwise comparison.
D) Validation of microarray results with quantitative
real-time RT-PCR. OE1, MIN6-Sir2OE1; OE2, MIN6-
Sir2OE2; KD1, MIN6-Sir2KD1; KD2, MIN6-Sir2KD2;
M, microarray; R, RT-PCR. Serpina1a, serine pro-
teinase inhibitor 1-1 (α1-antitrypsin); Arid1b, AT-rich
interactive domain 1B; Kcnmb4, large conductance
calcium-activated potassium channel b4; Mct1, sol-
ute carrier family 16 member 1 (monocarboxylic
acid transporter 1); Abcc3, ATP binding cassette
transporter c3; Prlr, prolactin receptor; Ucn3, uro-
cortin 3; Ucp2, uncoupling protein 2. All error bars
represent standard deviations.during IPGTTs and in situ pancreatic perfusion experiments.
When Ucp2 decreases in β cells, the uncoupling between res-
piration and ATP synthesis also decreases. This in turn causes
an increase in mitochondrial ATP production, which subse-
quently promotes insulin secretion (Zhang et al., 2001). There-
fore, we examined the effect of the observed decrease in Ucp2
on ATP production in BESTO islets. Consistent with the ob-
served decrease in Ucp2 levels, the BESTO islets had signifi-
cantly higher ATP levels compared to controls when stimulated
with 20 mM glucose (Figure 7C).
We then examined insulin secretion in response to both high
glucose and KCl in islets isolated from BESTO and control
mice. In response to 20 mM glucose, isolated BESTO islets
showed a statistically significant enhancement of insulin secre-
tion compared to controls (Figure 7D), although there was a
large variation in insulin secretion among the individual groups
of BESTO islets (Figure S1). The BESTO islets also showed an
increase in insulin content compared to controls when stim-112ulated with 20 mM glucose (Figure 7E). Strikingly, KCl stimula-
tion of isolated BESTO islets elicited an even more pronounced
increase in insulin secretion compared to controls (Figure 7D
and Figure S1). Consistent with the results from the IPGTTs
and the in situ pancreatic perfusion experiments, these find-
ings demonstrate that increased dosage of Sirt1 in β cells en-
hances the insulin secretion capability of isolated BESTO
islets.
Discussion
Increased dosage of Sirt1 in pancreatic β cells enhances
glucose-stimulated insulin secretion in vivo
In the present study, we have provided several lines of evi-
dence demonstrating that the mammalian Sir2 ortholog Sirt1
regulates glucose-stimulated insulin secretion in pancreatic β
cells. First, Sirt1 was expressed exclusively in pancreatic islets
and not in the pancreatic exocrine tissue, and Sirt1 was pres-CELL METABOLISM : AUGUST 2005
Sirt1 regulates pancreatic β cell function in miceFigure 7. Ucp2, ATP, and insulin measurements in isolated BESTO islets
A) Western blot analysis of Ucp2, Glut2, Kcmnb4, and Mct1 proteins in transgenic and control islet extracts from line 431-4. For each independent extract, islets were
pooled from two to three mice, and two to five independent Western blots were conducted. The asterisk represents a crossreacting band. Actin was used as a loading
control for normalization.
B) Quantitation of the independent Western blot results, normalized to actin.
C) ATP levels (pmol/g protein) in transgenic (black bars) and control (white bars) islets from line 431-4 in extracts collected after stimulation with the indicated
concentrations of glucose in insulin secretion assays (n = 4).
D) Insulin secreted (ng/ml/hr) from transgenic (black bars) and control (white bars) islets from line 431-4 at the indicated glucose or KCl concentrations (n = 8 for
glucose stimulation; n = 4 for KCl stimulation). The secretion assays were performed on triplicate groups of ten islets for each mouse.
E) Islet insulin content (ng/islet) of transgenic (black bars) and control (white bars) islets from line 431-4 in extracts collected after stimulation with the indicated
concentrations of glucose in insulin secretion assays (n = 4).
F) Proposed model for Sirt1-mediated regulation of insulin secretion in the β cell.
All results are expressed as mean ± SE. *p % 0.05, **p % 0.01, ***p % 0.001.ent in both the nucleus and cytoplasm of β cells (Figures 1B–
1H). Second, BESTO transgenic mice exhibited significantly
improved glucose tolerance and enhanced insulin secretion
when challenged with high glucose during IPGTTs at threeCELL METABOLISM : AUGUST 2005months of age (Figures 3C–3E). Third, in situ pancreatic perfu-
sion experiments further demonstrated that BESTO pancreata
have enhanced insulin secretion in response to both glucose
and KCl stimulation (Figure 4). Fourth, BESTO mice maintained113
A R T I C L Eenhanced glucose-stimulated insulin secretion compared to
controls at 8 months of age (Figures 5C–5E). Finally, isolated
BESTO islets exhibited enhanced insulin secretion in response
to both high glucose and KCl (Figure 7D). These data establish
that increased dosage of Sirt1 conveys beneficial effects on
mammalian physiology, particularly on glucose metabolism,
in vivo.
The phenotype observed in BESTO mice must primarily be
due to an alteration of β cell function. In BESTO mice, the dos-
age of Sirt1 was increased exclusively in pancreatic β cells
(Figure 2C). Additionally, islet area and β cell mass did not differ
between BESTO mice and their controls (Figures 2D and 2E).
Furthermore, results from the perfused pancreata and the iso-
lated islet experiments demonstrated that the enhanced insulin
secretion in BESTO mice was intrinsic to pancreatic islets and
not secondary to altered insulin sensitivity in insulin target tis-
sues such as liver or skeletal muscle (Figures 4 and 7D). There-
fore, the enhanced insulin secretion and improved glucose tol-
erance of BESTO mice must be due to changes in β cell
function rather than ectopic expression of Sirt1 in other tissues
or alterations in islet structure.
Genetic manipulations that overexpress proteins in pancre-
atic β cells can disrupt their structure and/or function. How-
ever, this is unlikely to be the case in BESTO mice. The in-
creased dosage of Sirt1 improved β cell function in response
to high glucose, and no physiological abnormalities were ob-
served. One interpretation of this phenotype is that increasing
Sirt1 dosage in β cells amplifies the normal Sirt1-mediated
physiological response to nutrients in β cells. Sirt1 might main-
tain the robustness of β cell function in the face of dietary chal-
lenges, such as rapid changes in blood glucose, lipids, and
amino acids after the ingestion of a nutrient-dense meal. In-
deed, isolated BESTO islets appear to be resistant to high
levels of free fatty acids (K.A.M. and S.-i.I., unpublished data).
Therefore, it would be of great interest to test whether BESTO
mice are more resistant to complications caused by high-car-
bohydrate or high-fat diets.
Mechanisms of insulin secretion altered by Sirt1
in pancreatic β cells
Sirt1 likely regulates β cell function through multiple mecha-
nisms. Transcriptional profiling of Sirt1-overexpressing and
Sirt1-knockdown β cell lines suggests that Sirt1 affects a vari-
ety of genes involved in the regulation of insulin secretion (Fig-
ure 6D). Western blot analyses of Ucp2, Glut2, Kcnmb4, and
Mct1 in isolated islets confirmed these changes in BESTO mice
(Figures 7A and 7B). Because minor changes in Glut2 expres-
sion are not sufficient to limit glucose utilization in islets (Guil-
lam et al., 2000), it is unlikely that the marginal decrease in
Glut2 protein levels in the BESTO islets would contribute to the
phenotype of the BESTO mice. The changes in Kcnmb4 and
Mct1 protein levels detected in isolated BESTO islets, as well
as other genes identified by the microarray analyses, might
contribute to the BESTO phenotypes. However, further investi-
gation will be necessary to understand these potential connec-
tions.
We were particularly interested in the decrease in Ucp2 ob-
served in the BESTO islets, because Ucp2-deficient mice have
improved glucose tolerance and enhanced insulin secretion
during IPGTTs, phenotypes similar to those of BESTO mice
(Zhang et al., 2001). Consistent with this observed decrease in114Ucp2, we also detected a significant increase in ATP levels in
response to high glucose in isolated BESTO islets (Figure 7C).
Glucose-induced ATP production initiates a prompt response
of the insulin secretory machinery in β cells by closing KATP
channels (see Figure 7F). While correlative, the observed in-
crease in first-phase insulin secretion in the perfused BESTO
pancreata is consistent with an enhancement of ATP produc-
tion by Sirt1. The observed increase in ATP levels might also
account for the increase in insulin secretion from isolated BE-
STO islets in response to glucose (Figure 7D). Additionally, Gu-
arente and his colleagues independently found that a reduction
in Sirt1 levels increases Ucp2 expression and decreases insulin
secretion in β cells (L. Bordone and L. Guarente, personal com-
munication). Taken together, the reduction of Ucp2 by Sirt1
likely contributes, at least in part, to the enhanced insulin
secretion in response to high glucose in BESTO mice (Fig-
ure 7F).
The observed increase in ATP levels could also explain the
increase in insulin content in isolated BESTO islets exposed to
high glucose (Figure 7E). It has been shown that static incuba-
tion of islets in high glucose induces proinsulin biosynthesis
within 1 hr at the level of translation (Wicksteed et al., 2003).
The mammalian target of rapamycin kinase, which is stim-
ulated by ATP during glucose stimulation (McDaniel et al.,
2002), has been suggested to be a potential downstream me-
diator of this effect (Wicksteed et al., 2003). Whether the in-
crease in ATP levels causes the increase in insulin content and
to what extent this change accounts for the increase in insulin
secretion in vitro remain to be determined.
Strikingly, KCl, which directly depolarizes β cells, elicited a
more pronounced increase in insulin secretion in both BESTO
pancreata and islets compared to the effect of glucose (Figures
4 and 7D). This suggests that Sirt1 also regulates insulin secre-
tion downstream of β cell depolarization, independently of
Ucp2 (Figure 7F). It has been proposed that nutrients, such as
free fatty acids and amino acids, also stimulate insulin secre-
tion through mechanisms downstream of depolarization (Yaney
and Corkey, 2003). Although we have not yet identified the mo-
lecular target of Sirt1 that acts downstream of depolarization,
this additional Sirt1-mediated mechanism might regulate insu-
lin secretion in vivo in response to these nutrients. Indeed, we
observed that the addition of free fatty acids during glucose
stimulation appeared to further augment the difference in insu-
lin secretion between BESTO and control islets (K.A.M. and
S.-i.I., unpublished data). Therefore, it is of great interest to
examine whether BESTO mice also show enhanced insulin
secretion in response to other nutritional stimulants.
Therapeutic potential for Sirt1 in pancreatic β cells
Aging is one of the greatest risk factors for obesity, glucose
intolerance, and type 2 diabetes (Chang and Halter, 2003;
Moller et al., 2003). In addition to increased abdominal adipos-
ity and decreased physical fitness, a progressive decline in β
cell function in the elderly is a major contributing factor to the
pathophysiology of type 2 diabetes (Basu et al., 2003; Iozzo et
al., 1999). A similar age-associated impairment of β cell func-
tion has also been demonstrated in rodents (Muzumdar et al.,
2004). The finding that Sirt1 improves β cell function at both 3
and 8 months of age provides insight into the development
of new dietary and pharmacological interventions to treat type
2 diabetes.CELL METABOLISM : AUGUST 2005
Sirt1 regulates pancreatic β cell function in miceBased on this and other studies, Sirt1 likely functions to pre-
serve a wide variety of cell-type- and tissue-specific functions.
Therefore, it would be of great importance to further investigate
the tissue-dependent effects of Sirt1 on mammalian physiology
by altering Sirt1 dosage/activity in tissue-specific transgenic
and knockout mice.
Experimental procedures
Generation of BESTO transgenic mice
The pIns-Sirt1 transgene was constructed by converting the EcoRI site to
SalI in the pIns-1 vector (Miyazaki et al. [1990], a gift from Dr. Jun-ichi Miya-
zaki, Osaka University, Japan) and inserting a 2.2 kb fragment of the mouse
Sirt1 cDNA that contains the entire coding region of Sirt1 into the SalI site.
In this vector, the Sirt1 cDNA is driven by the 1.9 kb human insulin promoter
(Hotta et al., 1998; Yamamoto et al., 2003). The pIns-Sirt1 transgene was
linearized with SphI and XhoI, purified, and microinjected into fertilized eggs
of C57BL/6 inbred mice in the Washington University Mouse Genetics Core
Facility. Transgenic mice were identified by PCR genotyping from tail DNA
using forward and reverse primers 5#-GCGGCTTGAGGGTAATCAATAC
CTGTTTGT-3# and 5#-TGATAGGCAGCCTGCACCTGAGGAGTGAAT-3#, re-
spectively. Two transgenic founders (lines 431-2 and 431-4) were estab-
lished and crossed to wild-type C57BL/6 mice (Jackson Laboratories). The
F1 and F2 generations from these lines were used for analysis, and non-
transgenic littermates were used as controls. All animal procedures were
approved by the Washington University Animal Studies Committee.
Islet morphometry analysis and total pancreatic insulin content
Pancreata were fixed and processed as described in the Immunohisto-
chemical Analysis section (see Supplemental Data). For each pancreas, in-
sulin staining was performed in five sections (5 m) separated by 200 m,
and the percent islet area and the β cell mass were quantitated as described
previously (Bernal-Mizrachi et al., 2001) using the BioQuant image analyzer
(BIOQUANT Image Analysis Corporation) and ImageJ (Girish and Vijaya-
lakshmi, 2004) software.
Total pancreatic insulin content was measured after acid-ethanol extrac-
tion of the whole pancreas, as described previously (Ma et al., 2004). Ex-
traction was repeated twice, and the supernatants were pooled and stored
at −20°C. The insulin concentration was measured by radioiummunoassay
in the Washington University Radioimmunoassay (RIA) Core Facility.
Fed and fasted glucose and insulin measurements
Fed glucose and insulin levels were measured between 9 and 10 a.m., while
fasted glucose and insulin levels were measured after 15 hr of overnight
fasting. Glucose levels were determined using the Accu-Chek II glucometer
(Roche Diagnostics) with blood collected from the tail vein. For determining
insulin levels, blood was collected from the tail vein into chilled heparinized
capillary tubes, and plasma was separated by centifugation and stored at
−80°C. Insulin levels were determined on 10 l aliquots using rat insulin
ELISA kits with mouse insulin standards (Crystal Chem Inc.) at the Washing-
ton University RIA Core Facility.
Intraperitoneal glucose tolerance tests
After mice were fasted for 15 hr, 50% dextrose (2 g/kg body weight) was
injected intraperitoneally. Blood was collected from the tail vein at 0, 15,
30, 60, and 120 min after injection for glucose measurements. Plasma for
insulin measurements was also collected at 0 and 30 min after glucose
injection and submitted to the Washington University RIA Core facility.
Insulin secretion from in situ-perfused pancreata
Pancreata were perfused via the aorta at the celiac artery in a humidified,
temperature-controlled chamber, as described previously (Johnson et al.,
2003). The perfusate consisted of oxygenated Krebs-Ringer bicarbonate
buffer (KRB), containing 119 mM NaCl, 4.7 mM KCl, 25 mM NaHCO3, 2.5
mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 0.25% radioimmuno-
assay grade BSA with either 2 or 25 mM glucose or 25 mM KCl. The perfu-
sion was maintained at a constant rate of 1 ml/min using Minipuls 3 peristal-
tic pumps. Prior to sample collection, the pancreas was perfused with 2
mM glucose/KRB for 45 min. The effluent was then collected at 1, 2, or 5CELL METABOLISM : AUGUST 2005min intervals, as indicated. The insulin concentration of each fraction was
determined by radioimmunoassay. The first phase was defined from the
earliest time point with an increased insulin secretion after the glucose stim-
ulus until the time point when insulin secretion plateaued after the first peak.
The second phase continued from this point until the end of glucose stimu-
lation (Spinas et al., 1998). The area under the curve (AUC) at each time
interval was calculated to determine the amount of insulin secreted during
glucose and KCl stimulation, and the Wilcoxon matched pairs test was em-
ployed for statistical analyses.
Glucose-stimulated insulin secretion and insulin content
from isolated islets
Islets were isolated by collagenase digestion. Briefly, pancreata were in-
flated with isolation buffer (10x HBSS, 10 mM HEPES, 1 mM MgCl2, 5 mM
glucose [pH 7.4]) containing 0.375 mg/ml collagenase (Sigma) via the pan-
creatic duct after clamping off its entry site to the duodenum. The inflated
pancreas was then removed, incubated at 37°C for 12–15 min, and shaken
vigorously. Islets were separated from acinar tissue after a series of washes
and passages through a 70 m nylon BD Falcon Cell Strainer (BD Biosci-
ences).
Handpicked islets were cultured overnight in RPMI media containing
either 5 or 11 mM glucose, 2 mM L-glutamine, penicillin/streptomycin, and
10% fetal bovine serum (FBS; GIBCO, Invitrogen). The islets were then pre-
incubated in KRB buffer containing 2 mM glucose for 1 hr at 37°C. Islets of
similar size were handpicked into groups of ten islets in triplicate and incu-
bated with 1 ml KRB buffer containing either 2 mM glucose, 20 mM glu-
cose, or 20 mM KCl plus 2 mM glucose for 1 hr at 37°C. The supernatant
was stored at −20°C prior to insulin measurements. After the insulin secre-
tion experiments, islets were washed two times with PBS and extracted
with acid-ethanol overnight at 4°C in order to measure insulin content. Insu-
lin levels of all samples were measured by radioimmunassay at the Wash-
ington University RIA Core Facility.
ATP measurements from isolated islets
Islets were pre-cultured in RPMI media containing 5 mM glucose, 2 mM
L-glutamine, penicillin/streptomycin, 0.25% fatty acid-free BSA, 0.4 mM
palmitate, and 5% FBS. After the insulin secretion experiments, islets were
washed two times with PBS and then extracted with extraction buffer
(0.1 M NaOH, 0.5 mM EDTA). After neutralizing the samples with 0.1 M HCl,
ATP levels were measured using the ATP Bioluminescent Assay Kit (Sigma)
according to the manufacturer’s instructions. Protein concentration of the
islets was determined, and ATP was normalized to the protein content.
Statistical analysis
Unless otherwise indicated, all values are expressed as mean ± standard
error (SE), and statistical analyses were carried out using an unpaired Stu-
dent’s t test. Differences were considered to be statistically significant when
p < 0.05.
Additional experimental procedures are provided in Supplemental Data.
Supplemental data
Supplemental data include one figure, two tables, supplemental experimen-
tal procedures, and supplemental references and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/2/2/105/
DC1/.
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